WealthTrust Asset Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 40.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,213 shares of the company’s stock after acquiring an additional 638 shares during the period. Eli Lilly and Company makes up 1.2% of WealthTrust Asset Management LLC’s portfolio, making the stock its 19th biggest holding. WealthTrust Asset Management LLC’s holdings in Eli Lilly and Company were worth $2,035,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Ascent Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 6.6% in the first quarter. Ascent Wealth Partners LLC now owns 8,706 shares of the company’s stock worth $8,008,000 after purchasing an additional 540 shares during the period. Paces Ferry Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 3.4% during the 1st quarter. Paces Ferry Wealth Advisors LLC now owns 429 shares of the company’s stock valued at $395,000 after purchasing an additional 14 shares during the period. Laidlaw Wealth Management LLC boosted its stake in Eli Lilly and Company by 11.6% during the 1st quarter. Laidlaw Wealth Management LLC now owns 946 shares of the company’s stock valued at $870,000 after purchasing an additional 98 shares during the period. Aviance Capital Partners LLC grew its holdings in Eli Lilly and Company by 12.0% in the 1st quarter. Aviance Capital Partners LLC now owns 2,378 shares of the company’s stock valued at $2,187,000 after buying an additional 254 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC grew its holdings in Eli Lilly and Company by 12.6% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 1,622 shares of the company’s stock valued at $1,492,000 after buying an additional 182 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on LLY shares. Royal Bank Of Canada upped their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. Rothschild & Co Redburn raised their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. UBS Group boosted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Citigroup upped their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.
Eli Lilly and Company Trading Up 0.8%
Eli Lilly and Company stock opened at $1,178.01 on Friday. The business has a 50 day moving average price of $1,118.87 and a two-hundred day moving average price of $1,036.80. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.11 trillion, a price-to-earnings ratio of 41.85, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the firm earned $3.34 EPS. Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 34.55 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.
More Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
- Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984
- Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
- Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
See Also
- Five stocks we like better than Eli Lilly and Company
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
